UnknownN/Aketamine
Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.
Sponsored by Centre Hospitalier Universitaire de Charleroi
NCT ID
NCT04938713
Target Enrollment
50 participants
Start Date
2021-07-01
Est. Completion
2022-09-30
About This Study
Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.
Conditions Studied
Interventions
- •Ketamine 50 MG/ML
- •Esketamine 25 MG/ML
Eligibility
Age:18 Years - 75 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Male and female * Between 18 and 75 years old * Reads and writes French * Diagnosis of fibromyalgia syndrome according to Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) score ≥ 13/31 * Both molecules (Ketamine and Esketamine) were administered at least once during an analgesic infusion session in Pain Clinic * Patient with regular medical follow-up by a pain specialist at least 3 times a year Exclusion Criteria: * Allergy or intolerance to Ketamine or Esketamine * Current infection, fever * Pregnant or breastfeeding woman * Serious cardiovascular disorders and severe hypertension * Increased pressure of cerebrospinal fluid and severe intracranial disease * Acute intermittent porphyria * Untreated epilepsy * Untreated glaucoma * Difficult or impossible intravenous access * Chronic Liver Disease Child-Pugh C
Study Locations (1)
CHU de Charleroi
Lodelinsart, Hainaut, Belgium